Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | AR | P10275 | 10/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | PGR | P06401 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3054200 | 0.95 | CYP3A4 (0.61) | CYP3A4MAPK1MAPTARTSHR | |
| SCHEMBL3055385 | 0.83 | CYP3A4 (0.49) | CYP3A4MAPK1MAPTARTSHR | |
| SCHEMBL3050000 | 0.82 | SIRT6 (0.43) | CYP3A4MAPK1MAPTARTSHR | |
| SCHEMBL8409225 | 0.82 | AR (0.45) | CYP3A4MAPK1MAPTARTSHR | |
| SCHEMBL3060140 | 0.81 | MAPT (0.59) | CYP3A4MAPK1MAPTARTSHR | |
| SCHEMBL11872742 | 0.81 | TSHR (0.48) | CYP3A4MAPK1MAPTARTSHR | |
| SCHEMBL5692492 | 0.81 | MAPT (0.42) | CYP3A4MAPK1MAPTARTSHR | |
| SCHEMBL3057299 | 0.80 | CNR2 (0.57) | CYP3A4MAPK1MAPTARTSHR | |
| SCHEMBL5452124 | 0.79 | MAPT (0.60) | CYP3A4MAPK1MAPTARTSHR | |
| SCHEMBL3049772 | 0.78 | AR (0.44) | CYP3A4MAPK1MAPTARTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148893-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2006-07-06 | — | — | US | claimed |
| EP-1654221-A2 | ANILINE DERIVATIVED ANDROGEN-, GLUCOCORTICOID-, MINERALCORTICOID- AND PROGESTERONE- RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-10 | — | — | EP | claimed |
| WO-2005000795-A2 | ANILINE DERIVATIVED ANDROGEN-, GLUCOCORTICOID-, MINERALCORTICOID- AND PROGESTERONE- RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-01-06 | — | — | WO | claimed |
| US-20100222434-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING AMYLOID-BETA PROTEIN ACCUMULATION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-09-02 | — | — | US | disclosed |
| EP-2210603-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING THE ACCUMULATION OF AMYLOID- B PROTEIN | Sumitomo Chemical Company, Limited (JP) | 2010-07-28 | — | — | EP | disclosed |
| US-20060148893-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2006-07-06 | — | — | US | disclosed |
| EP-1654221-A2 | ANILINE DERIVATIVED ANDROGEN-, GLUCOCORTICOID-, MINERALCORTICOID- AND PROGESTERONE- RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005000795-A2 | ANILINE DERIVATIVED ANDROGEN-, GLUCOCORTICOID-, MINERALCORTICOID- AND PROGESTERONE- RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222434-A1 | PHARMACEUTICAL COMPOSITION FOR INHIBITING AMYLOID-BETA PROTEIN ACCUMULATION | APP, PSEN1, BACE1 | CYP3A4 3707/4885MAPK1 1024/4885MAPT 10/4885 |
| US-20060148893-A1 | Chemical compounds | NR3C2, NR5A1, NR3C1 | CYP3A4 180/4885MAPK1 773/4885MAPT 1877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.